The article compiles various news updates on Trump's trade policies, stock market reactions to tariffs and economic data, and developments in tech companies like Microsoft, Palantir, and Meta.

The article highlights stock price movements for several companies following their quarterly financial results, including Palantir's 4.5% rise due to strong earnings, Hims & Hers Health's 11% drop after mixed results, and Vertex Pharma's 7% decline after halting a drug trial. It also mentions BioMarin's 4.8% gain and Kyndryl's 7% fall.

U.S. stock futures are up following a disappointing jobs report and the dismissal of the Bureau of Labor Statistics commissioner by President Trump. The jobs report showed weaker-than-expected payroll growth, while the Fed held rates steady. Key companies like Palantir and Vertex Pharmaceuticals are in focus as investors await earnings reports. Markets are closely watching macroeconomic data, with a focus on GDP, trade deficit, and employment figures.

The article discusses Palantir's earnings surpassing those of Nvidia and Broadcom as they navigate challenges related to Trump-era tariffs.

Palantir (NASDAQ: PLTR) reported second quarter EPS of $0.16, exceeding analyst estimates by $0.02, with revenue of $1B surpassing the $937.45M consensus. The company provided FY 2025 revenue guidance of $4.14B-$4.15B, up from the $3.90B consensus. Its stock closed at $160.66, up 567% year-to-date. InvestingPro's AI analysis suggests PLTR may be undervalued despite recent market performance.